[Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster]

The Japanese Society of Medical Oncology has conducted a questionnaire survey of its members over a 4-year period from 2020 to 2023 as part of the"Survey on the Impact of Anticancer Drug Therapy under the Spread of COVID-19 Infection". By summarizing the results of the questionnaire survey and reviewing the changes in cancer treatment in the aftermath of the COVID-19, focusing on the results of the 2023 survey which was conducted after the disease became category V infectious disease. It became clear that the COVID-19 not only had an impact on medical professionals and treatment choices but also had a significant impact on end-of-life care. This work was supported by MHLW Special Research Program (Grant Number JPMH20CA2046) and MHLW Research on Emerging and Re-emerging Infectious Diseases and Immunization(Program Grant Number JPMH21HA2011, JPMH23HA2011 and JPMH24HA2015).